A new breast cancer drug has proved promising in a study and could potentially bring hope to many with the condition using respite care.
The Genentech Inc drug, called GDC-0941, targets the PI3K gene in patients with advanced breast cancer.
Dr Daniel D Von Hoff told the the 47th annual meeting of the American Society of Clinical Oncology that results looked promising in the early phase I investigational study carried out at Virginia G Piper Cancer at Scottsdale Healthcare.
"We are very excited about personalizing therapy for breast cancer and gynecologic cancer patients with PI3K inhibitors," he said.
"The next step will be to test samples from breast cancer patients for PI3K mutations and treat those patients accordingly."
Meanwhile, research published in journal the Archives of Dermatology reported that physician-based screening was much more successful at finding cancers than patient self-detection.
Find the nearest Barchester care home